Therapure Biopharma Inc. Announces Collaboration with BioVectra Inc.

Canadian companies team up in specialty biologics development

TORONTO and CHARLOTTETOWN, Nov. 4 /PRNewswire/ - BioVectra Inc. and Therapure BioPharma Inc. have agreed to partner in the development of a PEGylated biologic drug target used for cancer treatments, with a goal of advancing the project to a regulatory filing stage, suitable for a marketing partner to add to its portfolio of biologic products.

Over the past five years, BioVectra has been developing proprietary technologies for PEGylation as a mechanism for drug delivery. The partnership with Therapure builds upon BioVectra's expertise in the production of modified biologic molecules using a proprietary MPEG technology.

Therapure, from its 130,000 sq. ft facilities in Mississauga, Ontario, adds proprietary purification techniques and impressive formulation, fill, and finish expertise in biologics handling.

"We are very excited about working with BioVectra," said Thomas Wellner, President and CEO of Therapure Biopharma. "They bring significant expertise in active pharmaceutical ingredient development and a high degree of competence and commitment to our partnership."

"Our current program for drug development depends on finding the right partners," said Dale Zajicek, COO and VP of Business Development for BioVectra. "We know we have made a good choice in Therapure Biopharma and we look forward to working together to further the development and commercialization of this product."

About Therapure Biopharma:

Therapure Biopharma Inc. is an integrated biopharmaceutical company that develops, manufactures, purifies, and packages therapeutic proteins. Therapure Biopharma acquired its Canadian-built and conceived facility from Hemosol Corporation, a specialist in therapies derived from hemoglobin, a blood protein. Therapure Biopharma applies scientific, manufacturing, and downstream purification expertise with an intimate understanding of advanced biology, complex proteins, and regulatory processes to develop effective and innovative solutions to advance products from discovery to market.

For more information, please visit: www.therapurebio.com

About BioVectra Inc.:

BioVectra Inc. is a growing Canadian biopharmaceutical company focused on contract manufacturing and product development of active pharmaceutical ingredients, pharmaceutical intermediates, and specialized bioreagents. Located in Prince Edward Island, BioVectra currently holds 8 Drug Master File filings and is an active supplier to most of the major pharmaceutical, biotechnology, and diagnostic companies in North America and Europe.

For more information, please visit: www.biovectra.com

CONTACT: Media Contact: Thomas Wellner, President and CEO, Therapure
Biopharma Inc., (905) 286-6204, ceo@therapurebio.com